



Third Quarter 2025 Results

November 6, 2025

enovis[™]

Creating Better Together™

Forward-looking Statements

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding Enovis' business, including with respect to the acquisition of LimaCorporate S.p.A.; the impact of public health emergencies and global pandemics; disruptions in the global economy caused by escalating geopolitical tensions including in connection with Russia's invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; changes in government trade policies, including the impact of tariffs; the impact of the current shutdown of the U.S. government or any future shutdowns; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Information

Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin, and organic sales growth (also referred to herein as organic growth). Adjusted net income and adjusted net income per diluted share refer to net income and net income per share, respectively, excluding net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of loss from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation ("MDR") fees and other costs; strategic transaction costs; stock-based compensation; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; property plant and equipment step-up depreciation, and fair value charges on acquired inventory; goodwill impairment charges; other (income) expense, net; and including the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin, which is subject to the same adjustments as adjusted net income. Adjusted EBITDA represents adjusted net income or loss from continuing operations excluding interest, taxes, and depreciation and amortization. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Adjusted gross profit represents gross profit excluding the fair value charges of acquired inventory, depreciation step-up of acquired fixed assets and the impact of restructuring and other charges. Adjusted gross profit margin is subject to the same adjustments as adjusted gross profit. Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures and foreign exchange rate fluctuations. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

Q3 2025 Highlights




- **+9% reported growth, +7% organic growth**
 - +9% organic growth in Recon
 - +4% organic growth in P&R
- **Another quarter of improving cash generation, ~\$30M in Free Cash Flow in Q3 25**
- **Encouraging execution from key new products**
 - Nebula and Surgical Impactor in Hip
 - ARG in Shoulder
 - ManaFuse in P&R

Continued Execution in Q3

Q3 Reconstructive Segment Sales Performance

Reconstructive Q3 Sales

Growth: +12% Y/Y, +9% organic




- **WW performance back to above market growth**
 - +9% organic growth
 - +7% global growth in Hip/Knee and DD global growth in Extremities
- **U.S. organic growth of 7%**
 - +13% Extremities growth led by Shoulder
 - -1% Hip/Knee decline impacted by prior year capital (~\$3M, ~700bps Y/Y)
 - MSD implant growth driven by Nebula/Orthodrive impactor and revision knees
- **International organic growth of 12%**
 - Continued execution supported by cross-selling and new product launches

Diversified Global Portfolio Growth

Q3 Prevention & Recovery Segment Sales Performance

P&R Q3 Sales

Growth: +6% Y/Y, +4% organic



- **WW organic growth of 4%**
 - Global Bracing growth of 4%
- **Adjusted Gross Margin expansion +110bps inclusive of tariff impact**
- **Encouraging progress shaping our portfolio for growth**
 - BoneStim
 - MotionMD and RCM
 - Spine bracing innovation

Proactively Shaping P&R

P&L Performance

<i>Millions</i>	<u>Q3 2024</u>	<u>Q3 2025</u>
Net Sales	\$505	\$549
Adj. Gross Profit Margin	\$298 58.9%	\$331 60.3%
Adj. EBITDA Margin	\$90 17.9%	\$95 17.3%
Adj. EPS	\$0.73	\$0.75

<i>Millions</i>	<u>YTD 2024</u>	<u>YTD 2025</u>
Net Sales	\$1,547	\$1,672
Adj. Gross Profit Margin	\$913 59.1%	\$1,017 60.8%
Adj. EBITDA Margin	\$264 17.0%	\$291 17.4%
Adj. EPS	\$1.86	\$2.36

Delivering Diversified Growth and Operating Efficiency

Shaping P&R For Profitable, Capital Efficient Growth



Financial Terms

- Total Transaction Value: Up to **\$60M**
- Upfront Cash Payment: **\$45M**
- Milestone Payments: Up to **\$15M**
- Effective Q4/25

Financial Impact

- | | |
|--------------------------------------|----------|
| • 2025 YTD Footcare Revenues | \$41M |
| • % of Prevention and Recovery | 4.8% |
| • % of Enovis | 2.4% |
| • Impact on Q4 2025 Revenue guidance | ~(\$15M) |

Strategic Rationale

- Strengthens focus on core Prevention & Recovery market leadership
- Shapes P&R for higher growth through portfolio optimization and improved operating efficiencies
- Sale proceeds used to support debt reduction

Full Year 2025 Outlook

	February	May	August	November
Reported Revenue	\$2.19-\$2.22B	\$2.22-\$2.25B	\$2.245-\$2.275B	\$2.24-\$2.27B
aEBITDA	\$405-\$415M	\$385-\$395M	\$392-\$402M	\$395-\$405M
Depreciation	\$125-\$130M	\$120-\$125M	\$120-\$125M	\$120-\$125M
Interest Expense	\$42-\$46M	\$38-\$42M	\$38-\$42M	\$38-\$42M
Effective Tax Rate	~23%	~23%	~23%	~23%
aEPS	\$3.10-\$3.25	\$2.95-\$3.10	\$3.05-\$3.20	\$3.10-\$3.25

Guidance Considerations

- Global markets grow in line with historical averages
 - Organic Growth = ~6.25-6.75% Y/Y
 - HSD Recon growth, P&R stable at LSD
 - ~\$15M revenue reduction from Diabetic Footwear Divestiture in Q4/25
- Fx = 1.25% -1.75% tailwind vs PY at current rates
- aEPS assumes shares of ~57M
- Positive free cash flow
- Includes planned tariff impact at currently proposed rates


Raising aEBITDA and aEPS guidance

Summary



- Solid execution in 3Q and YTD demonstrating the power of the diversified portfolio
- Global Recon growth above market fueled by recent launches
- Continuing to manage the dynamic global macroeconomic environment
- Raising aEBITDA and aEPS guidance
- Cash Flow improving

Appendix



enovis[™]

Creating Better Together™

QTD Sales Bridge

	Net Sales					
	Prevention and Recovery		Reconstructive		Total Enovis	
	\$	Change %	\$	Change %	\$	Change %
For the three months ended September 27, 2024	\$ 274.2		\$ 231.0		\$ 505.2	
<i>Components of Change:</i>						
Existing Businesses ⁽¹⁾	11.8	4.3 %	21.2	9.2 %	33.0	6.5 %
Acquisitions ⁽²⁾	1.1	0.4 %	—	— %	1.1	0.2 %
Divestitures ⁽³⁾	—	— %	—	— %	—	— %
Foreign Currency Translation ⁽⁴⁾	3.8	1.4 %	5.8	2.5 %	9.6	1.9 %
	<u>16.7</u>	<u>6.1 %</u>	<u>27.0</u>	<u>11.7 %</u>	<u>43.7</u>	<u>8.7 %</u>
For the three months ended October 3, 2025	<u>\$ 290.9</u>		<u>\$ 258.0</u>		<u>\$ 548.9</u>	

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

YTD Sales Bridge

	Net Sales					
	Prevention and Recovery		Reconstructive		Total Enovis	
	\$	Change %	\$	Change %	\$	Change %
For the nine months ended September 27, 2024	\$ 811.0		\$ 735.6		\$ 1,546.6	
<i>Components of Change:</i>						
Existing Businesses ⁽¹⁾	39.0	4.8 %	74.2	10.1 %	113.1	7.3 %
Acquisitions ⁽²⁾	2.8	0.3 %	—	— %	2.8	0.2 %
Divestitures ⁽³⁾	(4.3)	(0.5)%	—	— %	(4.3)	(0.3)%
Foreign Currency Translation ⁽⁴⁾	5.6	0.7 %	8.4	1.1 %	14.1	0.9 %
	<u>43.1</u>	<u>5.3 %</u>	<u>82.6</u>	<u>11.2 %</u>	<u>125.7</u>	<u>8.1 %</u>
For the nine months ended October 3, 2025	<u>\$ 854.1</u>		<u>\$ 818.2</u>		<u>\$ 1,672.3</u>	

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

QTD Adjusted EPS Reconciliation

	Three Months Ended		Nine Months Ended	
	October 3, 2025	September 27, 2024	October 3, 2025	September 27, 2024
Adjusted Net Income and Adjusted Net Income Per Share				
Net Loss (GAAP)	\$ (570.9)	\$ (31.3)	\$ (663.2)	\$ (121.6)
Net loss margin (GAAP)	(104.0)%	(6.2)%	(39.7)%	(7.9)%
Net income attributable to noncontrolling interest from continuing operations - net of taxes	(0.2)	(0.3)	(0.7)	(0.5)
Loss from discontinued operations, net of taxes	—	(2.2)	0.3	(2.2)
Net loss from continuing operations attributable to Enovis Corporation ⁽¹⁾ (GAAP)	\$ (571.1)	\$ (33.8)	(663.6)	\$ (124.3)
Restructuring charges - pretax ⁽²⁾	3.4	7.8	8.2	25.3
MDR and other costs - pretax ⁽³⁾	2.4	5.3	9.0	14.8
Amortization of acquired intangibles - pretax	43.7	42.8	128.5	124.7
Goodwill impairment charge	548.4	—	548.4	—
Inventory step-up and PPE step-up depreciation - pretax ⁽⁴⁾	0.7	9.1	20.0	40.2
Strategic transaction costs - pretax ⁽⁵⁾	15.7	21.4	41.2	65.0
Stock-based compensation	9.0	7.8	25.0	21.9
Purchase of royalty interest ⁽⁶⁾	—	—	45.8	—
Other (income) expense, net ⁽⁷⁾	(0.4)	(0.2)	0.5	(9.8)
Tax adjustment ⁽⁸⁾	(8.2)	(19.2)	(27.4)	(54.5)
Adjusted net income from continuing operations (non-GAAP)	<u>43.5</u>	<u>41.0</u>	<u>135.6</u>	<u>103.2</u>
Adjusted net income margin from continuing operations	7.9 %	8.1 %	8.1 %	6.7 %
Weighted-average shares outstanding - diluted (GAAP)	\$ 57,169	\$ 55,666	\$ 57,029	\$ 55,072
Net loss per share - diluted from continuing operations (GAAP)	\$ (9.99)	\$ (0.61)	\$ (11.64)	\$ (2.26)
Adjusted weighted-average shares outstanding - diluted (non-GAAP)	\$ 57,725	\$ 56,030	\$ 57,558	\$ 55,511
Adjusted net income per share - diluted from continuing operations (non-GAAP)	\$ 0.75	\$ 0.73	\$ 2.36	\$ 1.86

QTD Adjusted EPS Reconciliation

- (1) Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes.
- (2) Restructuring charges include \$1.5 million and \$1.7 million expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were \$2.7 million similar charges for the three and nine months ended September 27, 2024.
- (3) MDR and other costs includes (i) \$2.1 million and \$7.6 million for the three and nine months ended October 3, 2025 and \$3.5 million and \$12.3 million for the three and nine months ended September 27, 2024, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) \$0.4 million and \$1.4 million for the three and nine months ended October 3, 2025 and \$1.8 million and \$2.4 million for the three and nine months ended September 27, 2024, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
- (4) Includes \$18.1 million in inventory step-up charges for the nine months ended October 3, 2025 and \$0.7 million and \$1.1 million in PPE step-up depreciation in connection with acquired businesses for the three and nine months ended October 3, 2025, respectively. Includes \$8.4 million and \$37.4 million in inventory step-up charges in connection with acquired businesses for the three and nine months ended September 27, 2024, respectively.
- (5) Strategic transaction costs includes: (i) \$9.2 million and \$28.1 million for the three and nine months ended October 3, 2025 and \$17.5 million and \$55.1 million for the three and nine months ended September 27, 2024, respectively, related to non-recurring integration costs associated with the Lima Acquisition, which includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities, professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, and integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) \$6.1 million and \$11.8 million for the three and nine months ended October 3, 2025 and \$2.6 million and \$5.7 million for the three and nine months ended September 27, 2024, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) \$0.4 million and \$1.3 million for the three and nine months ended October 3, 2025 and \$1.3 million and \$4.2 million for the three and nine months ended September 27, 2024, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
- (6) In the first and second quarters of 2025, we completed strategic purchases of economic interest on future royalty payments in our intellectual property ("royalty interest") for a fixed price of \$56.5 million, which will be paid over nine years. We accrued a liability and recognized \$45.8 million charge for the net present value of the purchases for the nine months ended October 3, 2025.
- (7) Other (income) expense, net primarily includes the fair value gain on Contingent Acquisition shares, partially offset by the first quarter of 2024 loss on the non-designated forward currency hedge for managing exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition.
- (8) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 21.8% and 22.9% for the three and nine months ended October 3, 2025, respectively, and 19.7% and 21.9% for the three and nine months ended September 27, 2024, respectively.

QTD

Adjusted EBITDA

Reconciliation

	Three Months Ended		Nine Months Ended	
	October 3, 2025	September 27, 2024	October 3, 2025	September 27, 2024
	(Dollars in millions)			
Net loss (GAAP)	\$ (570.9)	\$ (31.3)	\$ (663.2)	\$ (121.6)
Net loss margin (GAAP)	(104.0)%	(6.2)%	(39.7)%	(7.9)%
Income (loss) from discontinued operations, net	—	(2.2)	0.3	(2.2)
Income tax expense (benefit)	4.0	(9.1)	13.0	(25.4)
Other (income) expense, net	(0.4)	(0.2)	0.5	(9.8)
Interest expense, net	8.8	11.1	27.3	48.0
Operating loss (GAAP)	\$ (558.5)	\$ (31.7)	\$ (622.1)	\$ (111.0)
Adjusted to add:				
Restructuring charges ⁽¹⁾	3.4	7.8	8.2	25.3
MDR and other costs ⁽²⁾	2.4	5.3	9.0	14.8
Strategic transaction costs ⁽³⁾	15.7	21.4	41.2	65.0
Stock-based compensation	9.0	7.8	25.0	21.9
Depreciation and other amortization	30.7	28.4	88.9	85.7
Amortization of acquired intangibles	43.7	42.8	128.5	124.7
Goodwill impairment charge	548.4	—	548.4	—
Purchase of royalty interest ⁽⁴⁾	—	—	45.8	—
Inventory step-up ⁽⁵⁾	—	8.4	18.1	37.4
Adjusted EBITDA (non-GAAP)	\$ 94.8	\$ 90.2	\$ 291.0	\$ 263.7
Adjusted EBITDA margin (non-GAAP)	17.3 %	17.9 %	17.4 %	17.0 %

- ⁽¹⁾ Restructuring charges include \$1.5 million and \$1.7 million expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were two and seven tenths similar charges for the three and nine months ended September 27, 2024.
- ⁽²⁾ MDR and other costs includes (i) \$2.1 million and \$7.6 million for the three and nine months ended October 3, 2025 and \$3.5 million and \$12.3 million for the three and nine months ended September 27, 2024, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) \$0.4 million and \$1.4 million for the three and nine months ended October 3, 2025 and \$1.8 million and \$2.4 million for the three and nine months ended September 27, 2024, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
- ⁽³⁾ Strategic transaction costs includes: (i) \$9.2 million and \$28.1 million for the three and nine months ended October 3, 2025 and \$17.5 million and \$55.1 million for the three and nine months ended September 27, 2024, respectively, related to non-recurring integration costs associated with the Lima Acquisition, which includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities, professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, and integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) \$6.1 million and \$11.8 million for the three and nine months ended October 3, 2025 and \$2.6 million and \$5.7 million for the three and nine months ended September 27, 2024, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) \$0.4 million and \$1.3 million for the three and nine months ended October 3, 2025 and \$1.3 million and \$4.2 million for the three and nine months ended September 27, 2024, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
- ⁽⁴⁾ In the first and second quarters of 2025, we completed strategic purchases of economic interest on future royalty payments in our intellectual property ("royalty interest") for a fixed price of \$56.5 million, which will be paid over nine years. We accrued a liability and recognized a \$10.0 million and \$45.8 million charge for the net present value of the purchases for the three and nine months ended October 3, 2025, respectively.
- ⁽⁵⁾ Includes \$18.1 million in inventory step-up charges for the nine months ended October 3, 2025 and \$0.7 million and \$1.1 million in PPE step-up depreciation in connection with acquired businesses for the three and nine months ended October 3, 2025, respectively. Includes \$8.4 million and \$37.4 million in inventory step-up charges in connection with acquired businesses for the three and nine months ended September 27, 2024, respectively.

QTD Adjusted Gross Margin Reconciliation (Unaudited)

	Three Months Ended		Nine Months Ended	
	October 03, 2025	September 27, 2024	October 03, 2025	September 27, 2024
Net sales	\$ 548.9	\$ 505.2	\$ 1,672.3	\$ 1,546.6
Gross profit	\$ 328.9	\$ 286.5	\$ 995.8	\$ 873.2
Gross profit margin (GAAP)	59.9 %	56.7 %	59.5 %	56.5 %
Gross profit (GAAP)	\$ 328.9	\$ 286.5	\$ 995.8	\$ 873.2
Inventory step-up and PPE step-up depreciation	0.6	8.4	19.8	37.4
Restructuring charges	1.5	2.7	1.7	2.7
Adjusted gross profit (Non-GAAP)	331.0	297.6	1,017.3	913.3
Adjusted gross profit margin (Non-GAAP)	60.3 %	58.9 %	60.8 %	59.1 %

Q3'25 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions
(Unaudited)

	Enovis Continuing Operations	Acquisition- Related Non- Cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Income Tax Adjustment ^d	Adjusted
Net sales	\$ 548.9	\$ —	\$ —	\$ —	\$ —	\$ 548.9
Cost of goods sold	220.0	(0.6)	(1.5)	—	—	217.9
Gross profit	328.9	0.6	1.5	—	—	331.0
<i>Gross margin</i>	59.9 %					60.3 %
Selling, general and administrative expense	263.6	—	(2.4)	(24.6)	—	236.6
Purchase of royalty interest	—	—	—	—	—	—
Research and development expense	29.7	—	—	—	—	29.7
Amortization of acquired intangibles	43.7	(43.7)	—	—	—	—
Restructuring and other charges	1.9	—	(1.9)	—	—	—
Goodwill impairment charge	548.4	—	—	(548.4)	—	—
Operating (loss) income	(558.4)	44.3	5.8	573.0	—	64.7
Interest expense, net	8.8	—	—	—	—	8.8
Other income, net	(0.4)	—	0.4	—	—	—
(Loss) income before taxes	(566.8)	44.3	5.4	573.0	—	55.9
Income tax (benefit) expense	4.0	—	—	—	8.2	12.2
Less: NCI income, net of taxes	0.2	—	—	—	—	0.2
Discontinued Operations	—	—	—	—	—	—
Net (loss) income attributable to Enovis	\$ (571.0)	\$ 44.3	\$ 5.4	\$ 573.0	\$ (8.2)	\$ 43.5

^a Removes impact of amortization of acquired intangibles, fair value charges of acquired inventory and PPE step-up depreciation.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$15.7, stock-based compensation expense of \$8.9, and a goodwill impairment charge of \$548.4

^d The effective tax rate used to calculate adjusted net income was 21.8%

Q3'24 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions
(Unaudited)

	Enovis Continuing Operations	Acquisition- Related Non- Cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Income Tax Adjustment ^d	Adjusted
Net sales	\$ 505.2	\$ —	\$ —	\$ —	\$ —	\$ 505.2
Cost of goods sold	218.8	(8.4)	(2.7)	—	—	207.7
Gross profit	286.5	8.4	2.7	—	—	297.5
<i>Gross margin</i>	56.7 %					58.9 %
Selling, general and administrative expense	249.9	(0.7)	(5.3)	(29.3)	—	214.6
Purchase of royalty interest	—	—	—	—	—	—
Research and development expense	20.5	—	—	—	—	20.5
Amortization of acquired intangibles	42.8	(42.8)	—	—	—	—
Restructuring and other charges	5.1	—	(5.1)	—	—	—
Operating (loss) income	(31.7)	51.9	13.1	29.3	—	62.5
Interest expense, net	11.1	—	—	—	—	11.1
Other income, net	(0.2)	—	0.2	—	—	—
(Loss) income before taxes	(42.6)	51.9	12.9	29.3	—	51.4
Income tax (benefit) expense	(9.1)	—	—	—	19.2	10.1
Less: NCI income, net of taxes	0.3	—	—	—	—	0.3
Discontinued Operations	—	—	—	—	—	—
Net (loss) income attributable to Enovis	\$ (33.8)	\$ 51.9	\$ 12.9	\$ 29.3	\$ (19.2)	\$ 41.0

^a Removes impact of amortization of acquired intangibles, fair value charges of acquired inventory and PPE step-up depreciation.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$21.4 and stock-based compensation expense of \$7.8.

^d The effective tax rate used to calculate adjusted net income was 19.7%

enovis™

Creating Better Together™